Chongqing PegBio Biotechnology

PegBio is a clinical-stage biopharmaceutical company based in China that focuses on developing innovative therapies for chronic metabolic diseases, including diabetes, obesity, and MASH. The company utilizes its proprietary PEGylation technology platform to design long-acting versions of peptides and proteins, significantly improving their pharmacokinetic profiles and patient compliance. Its lead candidate, PB-119, is a long-acting GLP-1 receptor agonist that has completed Phase 3 clinical trials for type 2 diabetes in China. PegBio is also advancing a robust pipeline of multi-agonist peptides and small molecules targeting gout and gastrointestinal disorders. The company maintains significant R&D and manufacturing operations in Suzhou and Chongqing to support its global clinical development strategy.